Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14002387 | 0.83 | SMN1; SMN2 (0.55) | GRM2LTA4HALDH1A1POLBNAAA | |
| SCHEMBL16881052 | 0.83 | GRM2 (0.53) | GRM2LTA4HALDH1A1POLBNR1I2 | |
| SCHEMBL259624 | 0.83 | GRM2 (0.53) | GRM2LTA4HALDH1A1POLBNR1I2 | |
| SCHEMBL5315528 | 0.83 | GRM2 (0.53) | GRM2LTA4HALDH1A1POLBNR1I2 | |
| SCHEMBL531434 | 0.82 | GRM2 (0.52) | GRM2LTA4HPOLBNAAAFAAH | |
| SCHEMBL4519506 | 0.81 | GRM2 (0.51) | GRM2LTA4HPOLBNAAAFAAH | |
| SCHEMBL30996376 | 0.79 | GRM2 (0.60) | GRM2POLBRAB9ASMN1; SMN2CMA1 | |
| SCHEMBL14687303 | 0.79 | GRM2 (0.50) | GRM2LTA4HALDH1A1POLBNR1I2 | |
| SCHEMBL16610628 | 0.79 | GRM2 (0.50) | GRM2LTA4HALDH1A1POLBNR1I2 | |
| SCHEMBL260552 | 0.78 | KCNJ1 (0.56) | GRM2ALDH1A1POLBKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227721-B1 | NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1227721-A4 | NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MERCK & CO INC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20030207859-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | BALKOVEC JAMES M (US) | 2003-11-06 | — | — | US | disclosed |
| US-6630510-B1 | Together with a beta-lactam antibiotic | MERCK & CO., INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1192128-A4 | THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS | MERCK & CO INC (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030078418-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | BALKOVEC JAMES M (US) | 2003-04-24 | — | — | US | disclosed |
| EP-1227722-A1 | NOVEL SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | Merck & Co., Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227721-A1 | NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | Merck & Co., Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1192128-A1 | THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020019543-A1 | Thiol derivative, metallo-beta-lactamase inhibitors | BALKOVEC JAMES M (US) | 2002-02-14 | — | — | US | disclosed |
| WO-2001030149-A1 | NOVEL SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001030148-A1 | NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-LACTAMASE INHIBITORS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2000076962-A1 | THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078418-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | SI, ME1, ALPI | GRM2 2567/4885LTA4H 614/4885ALDH1A1 79/4885 |
| US-20030207859-A1 | Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections | SI, ME1, ALPI | GRM2 2567/4885LTA4H 614/4885ALDH1A1 79/4885 |
| US-20020019543-A1 | Thiol derivative, metallo-beta-lactamase inhibitors | CBR1, LBR, CBR3 | GRM2 3881/4885LTA4H 283/4885ALDH1A1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.